UKALL14: implementing genetics in ALL research
Anthony Moorman, PhD, of Newcastle University, Newcastle, UK, discusses the current UKALL14 trial (NCT01085617) for adults aged 25-65 with acute lymphoblastic leukemia (ALL). The trial is the first of... Author: VJHemOnc Added: 07/18/2018
In this study, we utilized proximity-based labeling (BioID) combined with label-free quantitative MS to identify high confidence NSD2 interacting partners in MM cells. The top 24 proteins identified were involved in maintaining chromatin structure, transcriptional regulation, RNA pre-spliceosome assembly, and DNA damage. Among these, an important DNA damage regulator, poly(ADP-ribose) polymerase 1 (PARP1), was discovered. PARP1 and NSD2 have been found to be recruited to DNA double strand breaks upon damage and H3K36me2 marks are enriched at damage sites. We demonstrate that PARP1 regulates NSD2 via PARylation upon oxidati...
Oncogene, Published online: 15 August 2019; doi:10.1038/s41388-019-0921-4T-cell acute lymphoblastic leukemia displays autocrine production of Interleukin-7
Authors: Jin F, Du Z, Tang Y, Wang L, Yang Y Abstract Natural killer (NK)-based immunotherapeutic strategies are showing promise in the clinic, particularly against acute myeloid leukemia (AML). Similar treatments for T-cell acute lymphoblastic leukemia (T-ALL) have been less successful, which is due to the higher resistance of T-ALL blasts to the cytotoxic function of NK cells. Herein, microRNA-29b (miR-29b) upregulation was identified in NK cells in both neurogenic locus notch homolog protein 1 (Notch1)-T-ALL mice and patients with T-ALL. Furthermore, miR-29b expression levels were downregulated in T-ALL blast ce...
Publication date: Available online 12 August 2019Source: Gynecologic Oncology ReportsAuthor(s): Jamil Kazma, Cynae Johnson, Nitin Jain, Vasantha Lakshmi Gali, Ken H. Young, Amir A. JazaeriAbstractThe involvement of the cervix as a site of relapse for hematologic malignancies is rare. We herein present a case of relapsed B-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL) mimicking advanced cervical cancer. The patient is a 61-year-old female with history B-cell ALL and had multiple relapses confined to the bone marrow and had received several different chemotherapy regimens. She presented with lower abdominal pain after the...
Condition: Childhood Leukemia and Lymphoma Intervention: Sponsors: Rabin Medical Center; The Israeli Society for Pediatric Hematology-Oncology; International BFM Study Group Not yet recruiting
CD19-targeted chimeric antigen receptor modified T-cell (CD19 CAR-T cell) immunotherapy has shown excellent anti-tumor activity in patients with relapsed/refractory acute lymphoblastic leukemia (ALL)  and non-Hodgkin lymphoma (NHL) [3,4], which led to the approval of tisagenlecleucel (Kymriah ࣨ) and axicabtagene ciloleucel (Yescartaࣨ) by the USA Food and Drug Administration (FDA).
Conclusions: Maternal folic acid supplementation was found to have a protective effect against childhood acute lymphoblastic leukaemia. Thus, healthcare professionals are recommended to provide regular health education and health promotion to the community on the benefits of folic acid supplementation during pregnancy. PMID: 31396374 [PubMed - in process]